SI-BONE Announces Q3 2024 Financial Results Release
SI-BONE, Inc. (Nasdaq: SIBN), recognized as a frontrunner in addressing sacropelvic disorders, has made an exciting announcement regarding its upcoming third-quarter financial results. The company is set to share its financial performance data after market closure, specifically on a Tuesday.
What to Expect on Financial Call
Management will follow up this announcement with a conference call aimed at investors and stakeholders. This session is scheduled to start at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. During this call, company executives will provide insights into the financials as well as the strategic direction moving forward.
Listening to the Conference Call
Investors keen on participating in the call can register in advance. SI-BONE plans to provide a live audio webcast accessible on the company’s website, enabling more individuals to engage with the discussions and insights shared by the management team.
About SI-BONE, Inc.
SI-BONE has established itself as a global leader in innovative surgical technologies aimed at the treatment of sacropelvic disorders. Since the introduction of minimally invasive surgery for the sacroiliac (SI) joint in 2009, the company has successfully assisted over 3,900 surgeons in executing more than 100,000 procedures worldwide. Such extensive experience not only exemplifies the effectiveness of its solutions but also underscores the trust the medical community places in the company’s offerings.
Clinical Evidence and Innovations
The foundation of SI-BONE’s credibility lies in a robust body of clinical evidence supporting its pioneering technologies. This includes two randomized controlled trials along with over 135 peer-reviewed publications. Such research and clinical data reinforce the effectiveness and safety of the company’s products and methods.
Expanding Into Adjacent Markets
Aside from its primary focus on SI joint fusion, SI-BONE is continuously innovating and has begun to explore adjacent markets. These include solutions for adult deformity, spinopelvic fixation, and pelvic trauma. By expanding its range, SI-BONE not only addresses a wider spectrum of orthopedic issues but also continues to reinforce its reputation as a versatile and progressive company in medical technology.
Investor Relations and Contact Information
Investors and interested parties are encouraged to reach out with inquiries regarding SI-BONE. The company emphasizes transparent communications and is open to addressing any questions or clarifications needed about its operations and products.
For further information, you can contact Saqib Iqbal regarding investor inquiries at investors@si-bone.com.
Frequently Asked Questions
When will SI-BONE report its Q3 2024 financial results?
SI-BONE will report its financial results after market close on November 12, 2024.
How can I listen to the financial conference call?
To listen to the call, you will need to register and access it through the company's website where it will be broadcasted live.
What technologies does SI-BONE specialize in?
SI-BONE specializes in surgical technology for sacropelvic disorders, particularly focusing on procedures involving the SI joint.
How many procedures has SI-BONE assisted with?
SI-BONE has supported surgeons in performing over 100,000 sacropelvic procedures worldwide.
What is the contact for investor relations?
For investor inquiries, Saqib Iqbal can be contacted at investors@si-bone.com.
